Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Three Period Crossover Thorough QT (TQT) Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

NCT03985410 is registered in ClinicalTrials.gov with Entasis Therapeutics as lead sponsor.

NCT NCT03985410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03985410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Three Period Crossover Thorough QT (TQT) Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers
Lead sponsor
Entasis Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 23, 2019
Completion date
July 24, 2019
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acinetobacter baumannii-calcoaceticus complex infections